Cytokines Play Integral Role in Cancer Immune Cycle
In the setting of cancer, cytokines contribute to cells’ antitumor response, cell damage, inflammation, angiogenesis, metastasis, and other cellular processes that enable tumor survival
Some Types of Prostate Cancer May Not be as Aggressive as Originally Thought
Researchers at the UCLA Jonsson Comprehensive Cancer Center analyze gene-expression patterns in the most aggressive prostate cancer grade group—known as Gleason grade group 5—and found that this grade of cancer can actually be subdivided into four subtypes with distinct differences.
FDA Approves Brigatinib for Frontline ALK+ NSCLC
The FDA has approved brigatinib for the first-line treatment of patients with ALK-positive metastatic non–small cell lung cancer, as detected by an FDA-approved test.
CLR 131 Mechanism of Action
New Treatment Extends Lives of People With Most Common Type of Liver Cancer
For the first time in over a decade, scientists have identified a first-line treatment that significantly improves survival for people with hepatocellular carcinoma, the most common type of liver cancer.
Roswell Park to Assess Immunotherapy Combination in Cancer Patients With COVID-19
A unique two-drug immunotherapy combination first evaluated at Roswell Park Comprehensive Cancer Center as an approach for treating some cancers will soon be available to cancer patients with COVID-19 through a clinical trial at Roswell Park.
Novel and Emerging Therapeutic Interventions in Relapsed and Refractory Diffuse Large B-Cell Lymphoma
A panel of experts discuss the current and emerging treatment landscape of relapsed/refractory diffuse large B-cell lymphoma.
Treatment Selection, Sequencing, and, Unmet Needs in GEP-NETs
Hagen F. Kennecke, MD, discusses treatment selection, peptide receptor radionuclide therapy, and remaining challenges in the field of gastroenteropancreatic neuroendocrine tumors.
Expert Explains Latest Treatment Strategies in GEP-NETs
Aman Chauhan, MD, discusses recent developments and emerging therapies in gastroenteropancreatic neuroendocrine tumors.
Current and Emerging Treatments for Gastroenteropancreatic Neuroendocrine Tumors
During an OncLive® scientific interchange, panelists discussed the current treatment landscape for patients with gastroenteropancreatic-neuroendocrine tumors and the need for improved novel therapies.
Bispecific CD19/CD22 CAR T Cells Active in Pediatric Relapsed ALL
Treatment with CD19/22 chimeric antigen receptor CAR T cells induced a promising response in patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
SKCC Welcomes Dr. Kristin Brill as Enterprise Director of Breast Oncology
Breast surgeon Kristin L. Brill MD, has joined the Sidney Kimmel Cancer Center – Jefferson Health as Enterprise Director of Breast Oncology.
Dana-Farber Cancer Institute Faculty Recognized as 2020 ASCO Leaders in Cancer Care
The American Society of Clinical Oncology recognized four Dana-Farber Cancer Institute researchers as winners of ASCO's Special Awards, the Society’s highest honors.
Roswell Park Physicians Asked to Share Expertise in National Leadership Roles
Two Roswell Park Comprehensive Cancer Center physicians are expanding their leadership roles across the United States and abroad with recent appointments in their respective fields of specialty.
OncLive News Network: On Location ASCO 2020
Join us LIVE at this year's virtual scientific program! OncLive® will broadcast a series of interviews with top thought leaders to share their insights and reactions to data presented during the virtual conference.
FDA Approves Mitomycin Gel for Urothelial Cancer
The FDA has approved mitomycin gel (Jelmyto) as the first therapy to treat low-grade upper tract urothelial cancer.
Margarett C. Ellison, MD of Gynecologic Oncology of Tallahassee Joins Florida Cancer Specialists and Research Institute
Florida Cancer Specialists & Research Institute is pleased to announce the addition of gynecologic-oncologist Dr. Margarett C. Ellison in Tallahassee.
Florida Cancer Specialists Launches Telehealth Services in Response to Coronavirus (COVID-19)
Florida Cancer Specialists & Research Institute recently launched telehealth services across all Florida Cancer Specialists & Research Institute sites statewide, allowing patients continued and convenient access to care, while mitigating the impact and spread of COVID-19.
The US Oncology Network Names Renowned Cancer Researcher Robert L. Coleman, MD, Chief Scientific Officer
The US Oncology Network (The Network) has named prominent cancer researcher Robert L. Coleman, MD, FACOG, FACS, as its new Chief Scientific Officer.
Please Donate Blood!
Amid the COVID-19 pandemic and in an effort to help our community, OncLive's parent company will be hosting the virtual MJH Life Sciences Sleeves Up Blood Drive from March 31 through April 30.
Roswell Park's Dr. Pawel Kalinski to Lead $14.5M NCI-Funded Immunotherapy Effort
A team led by Pawel Kalinski, MD, PhD, of Roswell Park Comprehensive Cancer Center has earned a five-year, $14.54 million award from the National Cancer Institute to expand a promising immunotherapy platform.
Expert Perspectives in the Evolving ALK+ NSCLC Paradigm
In a wide-ranging discussion, Alexander Drilon, MD; Julia Rotow, MD; Thomas E. Stinchcombe, MD; and Ashish Saxena, MD, PhD, provide expert insight on developments in ALK-positive non–small cell lung cancer.
OncLive and The Ruesch Center for the Cure of Gastrointestinal Cancers Names the 2020 Honorees of the Luminary Awards in GI Cancers
OncLive, in conjunction with The Ruesch Center for the Cure of Gastrointestinal Cancers, honored five individuals with a 2020 Luminary Award in Gastrointestinal Cancers for their commitment to the gastrointestinal cancer community.
BTK Inhibitors Transform Treatment in CLL, MCL, and Waldenstrom Macroglobulinemia
Constantine S. Tam, MD, MBBS, highlights the impact of BTK inhibitors in chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenström macroglobulinemia.
Updates in the ALK-Positive NSCLC Paradigm
Advanced, recurrent, and metastatic NSCLC is often associated with poor prognosis, and treatment is aimed to extend survival and provide symptom management.
An Expert Assessment of Available BTK Inhibitors Within the CLL Treatment Spectrum
Brad S. Kahl, MD, discusses the use of BTK inhibitors, which have revolutionized the treatment paradigm in chronic lymphocytic leukemia.
Exploring the Role of BTK Inhibitors in B-Cell Lymphomas
During an OncLive® Scientific Interchange, community and academic oncologists review the current treatment landscape and evaluate therapeutic strategies involving BTK inhibitors in B-cell lymphomas.
Experts Weigh In on Top Abstracts From Genitourinary Cancers Symposium
How to best pair immune checkpoint inhibitors with other agents known to have efficacy in genitourinary cancers was a key avenue of inquiry of many of the studies presented at the 2020 Genitourinary Cancers Symposium.
Randall A. Oyer, MD, Becomes President of the Association of Community Cancer Centers
Randall A. Oyer, MD, was named the Association of Community Cancer Centers (ACCC) President for 2020-2021 at the ACCC 46th Annual Meeting & Cancer Center Business Summit held March 4-6 in Washington, D.C.
From Scorpion to Immunotherapy: City of Hope Scientists Repurpose Nature's Toxin for First-Of-Its Kind CAR T Cell Therapy to Treat Brain Tumors
City of Hope scientists have developed and tested the first CAR T-cell therapy using chlorotoxin, a component of scorpion venom, to direct T cells to target brain tumor cells.
PVd Extends OS and PFS in Relapsed/Refractory Multiple Myeloma
At Multiple Dose Levels, Mezigdomide Elicits Responses in Combination With Bortezomib or Carfilzomib in R/R Myeloma
Durcabtagene Autoleucel Demonstrates Rapid Proliferation and Persistence in Relapsed/Refractory Myeloma
Systemic Review Sheds Light on Efficacy of Bispecific Antibodies in Extramedullary R/R Multiple Myeloma
2 Clarke Drive Cranbury, NJ 08512